Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hepatocyte nuclear factor 1-beta (HNF1B) is a transcription factor in the homeodomain-containing protein family, essential for the regulation of gene expression in multiple organs including the kidneys, pancreas, liver, and urinary and genital tracts[2][3][4][6]. HNF1B binds DNA as a homodimer or heterodimer and regulates genes crucial to organ development and function[2][3][4]. Mutations in HNF1B are associated with autosomal dominant monogenic diabetes (MODY5), renal cysts and diabetes syndrome (RCAD), and congenital kidney/urinary tract anomalies (CAKUT)[3][4]. Besides its developmental roles, HNF1B dysfunction can alter insulin secretion and nephron development, and has been linked to certain cancers, e.g. prostate cancer[3]. As a transcription factor, it is not directly targeted by current medicines, but its mutation status is an important biomarker for clinical diagnosis, genetic counseling, and patient management in related syndromes[3][4].
Not a direct drug target; gene mutations affect regulatory pathways for insulin and renal function
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatocyte nuclear factor 1-beta (HNF1B).